Company Analysis
Sign in

Enanta Pharmaceuticals, Inc. (ENTA)

Nasdaq: ENTA · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2002
Full chart Alerts Compare
Grade5.2
◀ Past 5.6● Present 5.0▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

292 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Enanta Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
292
291 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
11
Against 20 in 2024 and 9 in 2023
Applications published
213
13 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry53
Pharmaceuticals21
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Enanta Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
292 granted
38 published
Enanta Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
175 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,470Antiviral heterocyclic compoundsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Dec 16, 202512,496,282Hepatitis B antiviral agentsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Nov 25, 202512,479,854Spiropyrrolidine derived antiviral agentsPharmaceuticalsEnanta Pharmaceuticals, Inc.
Nov 4, 202512,459,923Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereofPharmaceuticalsEnanta Pharmaceuticals, Inc.
Aug 26, 202512,398,147Macrocyclic spiropyrrolidine derived antiviral agentsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Aug 12, 202512,384,75317-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereofOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Jul 15, 202512,358,921Antiviral heterocyclic compoundsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
May 13, 202512,297,209Benzodiazepine derivatives as RSV inhibitorsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Apr 22, 202512,281,140Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofPharmaceuticalsEnanta Pharmaceuticals, Inc.
Apr 8, 202512,268,694Combination pharmaceutical agents as RSV inhibitorsPharmaceuticalsEnanta Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/037645217-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use ThereofOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Dec 4, 20252025/0368659Antiviral Heterocyclic CompoundsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Oct 23, 20252025/0326768Benzodiazepine Derivatives as RSV InhibitorsPharmaceuticalsEnanta Pharmaceuticals, Inc.
Oct 9, 20252025/0313569Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2Organic fine chemistryEnanta Pharmaceuticals, Inc.
Oct 2, 20252025/0304600PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORSPharmaceuticalsEnanta Pharmaceuticals, Inc.
Oct 2, 20252025/0304542Fused Heterobicyclic Antiviral AgentsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
May 15, 20252025/0154163Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 InhibitorsOrganic fine chemistryEnanta Pharmaceuticals, Inc.
May 8, 20252025/0145603CRYSTAL FORMS OF AN ANTI-RSV AGENTOrganic fine chemistryEnanta Pharmaceuticals, Inc.
Apr 17, 20252025/012095217-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors And Methods Of Use ThereofPharmaceuticalsEnanta Pharmaceuticals, Inc.
Feb 20, 20252025/0059174Pharmaceutical Compounds and Compositions as C-Kit Kinase InhibitorsPharmaceuticalsEnanta Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 17 · Pharmaceuticals 13.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ENTA · research, not advice